Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NICE technology appraisal guidance 375
National Institute for Health and Care Excellence (NICE)
Record ID 32018011477
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta375
Year Published:
2016
URL for published report:
https://www.nice.org.uk/guidance/ta375
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Arthritis, Rheumatoid
- Adalimumab
- Etanercept
- Infliximab
- Certolizumab Pegol
- Abatacept
- Drug Therapy, Combination
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Methotrexate
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.